SR-9009 (Stenabolic) + SR-9011 (REV-ERB Agonist) + GW-0742 (Fitorine) | Metabolic Research UK

Advanced Metabolic Activity Research Set

The BioPlex Advanced Metabolic Activity Research Set combines SR-9009 (Stenabolic) 50×15mg, SR-9011 (REV-ERB Agonist) 50×15mg and GW-0742 (Fitorine) 50×15mg, bringing together three synthetic research compounds associated with nuclear-receptor signalling, circadian regulation and metabolic research. The set contains one pot of each compound and provides a structured triple-compound format for comparative laboratory investigation across two distinct areas of molecular signalling.

SR-9009 and SR-9011 are closely associated with research involving REV-ERBα and REV-ERBβ. These nuclear receptors participate in transcriptional networks connecting the molecular circadian clock with metabolic regulation. Synthetic ligands associated with REV-ERB research have consequently been investigated across experimental models examining circadian gene expression, metabolic signalling and related cellular processes.

GW-0742 provides a different molecular pathway. The compound is primarily associated with peroxisome proliferator-activated receptor delta, commonly abbreviated PPARδ. This nuclear receptor participates in transcriptional pathways involving lipid handling, fatty-acid metabolism and cellular-energy regulation.

Importantly, none of these three compounds is scientifically classified as a selective androgen receptor modulator. Their inclusion within broader research-compound categories should not be confused with androgen-receptor pharmacology.

The Advanced Metabolic Activity Research Set therefore creates a multi-pathway research framework rather than combining three compounds with an identical molecular target.

The set name reflects their shared relevance to experimental metabolic research and does not establish a predetermined combined response. Each compound retains its own molecular identity, evidence profile and research limitations, allowing REV-ERB-associated and PPARδ-associated signalling to be investigated independently and comparatively.

How SR-9009, SR-9011 and GW-0742 Work Together

SR-9009, SR-9011 and GW-0742 create a particularly interesting research combination because the three compounds connect two separate nuclear-receptor systems with broader metabolic and transcriptional biology. SR-9009 and SR-9011 are associated with REV-ERB research, while GW-0742 provides a separate PPARδ-associated pathway.

REV-ERBα and REV-ERBβ form part of the molecular machinery connecting circadian timing with transcriptional regulation. Experimental research involving synthetic REV-ERB ligands has examined how pharmacological manipulation of these pathways corresponds with changes in metabolic gene expression, cellular-energy processes and other predefined biological markers.

SR-9009 and SR-9011 provide two related but individually distinct compounds for investigating this area. Their relationship does not mean their pharmacological behaviour is necessarily identical. Differences in molecular structure, concentration-response relationships, cellular exposure and potential off-target activity can influence experimental observations.

GW-0742 expands the research framework through PPARδ. PPARδ belongs to the nuclear-receptor superfamily but operates through a distinct regulatory system associated with expression of genes involved in lipid and fatty-acid metabolism and broader cellular-energy processes.

The three compounds therefore allow REV-ERB-associated observations to be considered alongside PPARδ-associated observations within a common metabolic research theme.

This does not establish synergy. It would be scientifically inappropriate to assume that simultaneous investigation of these pathways automatically produces an enhanced metabolic response. The interaction between transcriptional systems is complex and dependent upon experimental model, receptor expression, concentration and methodology.

The value of this triple set instead lies in comparative pathway investigation: two related REV-ERB research compounds alongside a distinct PPARδ research compound, providing a broader framework for controlled investigation of metabolic and nuclear-receptor signalling.

SR-9009 (Stenabolic) 50×15mg

SR-9009, commonly known as Stenabolic, is a synthetic research compound developed during investigation of the nuclear receptors REV-ERBα and REV-ERBβ. Although frequently grouped commercially alongside SARMs, SR-9009 is not a selective androgen receptor modulator and should not be described as operating principally through androgen-receptor signalling.

REV-ERB receptors participate in transcriptional networks linking circadian regulation with metabolic processes. These receptors form part of the molecular machinery governing rhythmic gene expression and have consequently attracted research interest in relation to metabolic biology.

Early experimental research involving SR-9009 investigated whether synthetic pharmacological modulation of REV-ERB-associated pathways could correspond with changes in measurable circadian and metabolic endpoints. This generated interest in metabolic gene expression, mitochondrial-associated processes, energy regulation and other related cellular markers.

However, the mechanistic interpretation of SR-9009 requires caution. Later experimental research has reported SR-9009-associated effects in systems where functional REV-ERB activity was absent or disrupted. These observations suggest that some effects associated with SR-9009 may occur through mechanisms that are not exclusively dependent upon REV-ERB.

An observed experimental response following SR-9009 exposure therefore should not automatically be considered proof of direct REV-ERB-mediated activity.

Within the Advanced Metabolic Activity Research Set, SR-9009 provides one of two REV-ERB-associated research components. SR-9011 provides a related compound for comparison, while GW-0742 introduces the separate PPARδ pathway.

This three-way structure enables SR-9009 findings to be interpreted within a broader metabolic research framework while retaining appropriate compound-specific controls and distinguishing observed responses from conclusions about precise molecular mechanisms.

SR-9011 (REV-ERB Agonist) 50×15mg

SR-9011 is a synthetic research compound developed within the broader investigation of REV-ERBα and REV-ERBβ nuclear receptors. It is commonly described within experimental literature as a synthetic REV-ERB ligand or agonist and has been investigated in connection with circadian signalling, transcriptional regulation and metabolic biology.

REV-ERB receptors participate in the molecular circadian system and contribute to networks regulating rhythmic gene expression. Their relationship with metabolic pathways has made them important experimental targets for researchers investigating the connection between biological timing and cellular metabolism.

SR-9011 provides a second synthetic compound associated with this receptor system alongside SR-9009. Although their research histories overlap, the two molecules should remain individually identified. Structurally related compounds can differ in receptor interaction, concentration-response characteristics, cellular availability and potential off-target behaviour.

This distinction is particularly important within comparative research. Results obtained with SR-9009 cannot automatically be transferred to SR-9011, even where both compounds are investigated under a common REV-ERB-associated research theme.

SR-9011 is also not a SARM. Its principal research classification concerns REV-ERB-associated nuclear-receptor biology rather than selective modulation of the androgen receptor.

Within the Advanced Metabolic Activity Research Set, SR-9011 provides the second REV-ERB-focused component. Researchers can compare its experimental characteristics with SR-9009 before considering observations alongside the distinctly different PPARδ-associated profile of GW-0742.

This arrangement provides a broader laboratory framework for examining metabolic transcriptional signalling without treating three separate compounds as pharmacologically interchangeable.

SR-9011 consequently contributes both a direct comparison point for SR-9009 and a contrasting research pathway when considered alongside GW-0742.

GW-0742 (Fitorine) 50×15mg

GW-0742, presented within the BioPlex research range as Fitorine, is a synthetic research compound associated primarily with peroxisome proliferator-activated receptor delta, commonly abbreviated PPARδ. Its molecular classification is distinct from both selective androgen receptor modulators and the REV-ERB-associated compounds included elsewhere in this set.

PPARδ belongs to the nuclear-receptor superfamily and functions as a transcriptional regulator. Research involving this receptor has examined pathways associated with lipid handling, fatty-acid metabolism, cellular-energy regulation and expression of metabolically relevant genes.

GW-0742 has consequently been used experimentally as a pharmacological research tool for investigating PPARδ-associated signalling and determining how receptor modulation corresponds with changes in predefined molecular and cellular endpoints.

Its inclusion within the Advanced Metabolic Activity Research Set expands the scientific scope beyond the REV-ERB pathway represented by SR-9009 and SR-9011.

Rather than studying three compounds directed toward one receptor family, researchers can examine two related REV-ERB-associated compounds and compare their observations with a separate PPARδ-associated experimental pathway.

GW-0742 should therefore not be described as possessing the same mechanism as SR-9009 or SR-9011. Nor does the inclusion of all three compounds establish a synergistic interaction.

Experimental responses involving GW-0742 depend upon factors including receptor expression, compound concentration, exposure, cellular environment and methodology. Potential off-target activity and model-specific findings should also be considered when interpreting results.

Within this triple research set, GW-0742 provides the PPARδ-focused component and creates the multi-pathway aspect of the combination. Together, the three compounds support comparative investigation of distinct nuclear-receptor systems associated with metabolic and cellular-energy research.

Explore Related Research Compounds

Continue exploring related metabolic and nuclear-receptor research compounds from the BioPlex range.

View SR-9009 Stenabolic 50×15mg Research Capsules ⟶

View SR-9011 REV-ERB Agonist 50×15mg Research Capsules ⟶

View GW-0742 Fitorine 50×15mg Research Capsules ⟶

Explore BioPlex Research Information

Access BioPlex research guidance, compound classification and the complete research product range.

Read the Complete SARMs UK Research Compound Guide ⟶

Explore the BioPlex SARMs & Research Compound Range ⟶

View All BioPlex Research Products ⟶

Explore Related Research Articles

Continue your research with BioPlex articles covering metabolic research compounds, nuclear-receptor signalling and the scientific classification of compounds sold alongside SARMs.

Read the Complete SARMs UK Research Compound Guide ⟶

Explore BioPlex SARMs & Research Compound Articles ⟶

Disclaimer

For research purposes only. Not for human consumption.